World's Best Scientists 2026 revealed!
Geoffrey I. Shapiro

Geoffrey I. Shapiro

D-Index & Metrics

Medicine

D-Index
121
Citations
65152
World Ranking
3563
National Ranking
1961

Overview

Geoffrey I. Shapiro is affiliated with Harvard University in the United States and has an extensive research portfolio primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. The main focus of their work lies in Oncology, Molecular Biology, and Pulmonary and Respiratory Medicine, covering a broad range of subfields including Cancer Research and Pathology and Forensic Medicine.

Shapiro's research topics encompass several key areas within cancer biology and treatment strategies. These include:

  • PARP inhibition in cancer therapy
  • DNA Repair Mechanisms
  • Cancer Genomics and Diagnostics
  • Advanced Breast Cancer Therapies
  • Cancer-related Molecular Pathways
  • Protein Degradation and Inhibitors
  • Lung Cancer Treatments and Mutations

Their recent publications demonstrate engagement with cutting-edge oncology topics, with papers such as:

  • "KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors" (2020), published in the New England Journal of Medicine
  • "Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer" (2021), published in Cell
  • "Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration" (2020), published in Nature Medicine
  • "Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer" (2020), published in Nature Communications
  • "A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors" (2021), published in Nature Cancer

Their publication record includes frequent appearances in prominent journals such as:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Annals of Oncology
  • Nature Communications

Collaboration is a notable aspect of Shapiro's career, with frequent co-authors including:

  • Alan D. D'Andrea
  • Bose Kochupurakkal
  • James M. Cleary
  • Jennifer L. Guerriero
  • S. Percy Ivy

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  • BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.

    D Li;L Ambrogio;L Ambrogio;T Shimamura;S Kubo

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Cyclin-dependent kinase pathways as targets for cancer treatment.

    Geoffrey I. Shapiro

  • Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

    Esra A. Akbay;Esra A. Akbay;Shohei Koyama;Julian Carretero;Abigail Altabef;Abigail Altabef

  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

    David S. Hong;Marwan G. Fakih;John H. Strickler;Jayesh Desai

  • LKB1 modulates lung cancer differentiation and metastasis

    Hongbin Ji;Matthew R. Ramsey;D. Neil Hayes;Cheng Fan

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • Targeting CDK4 and CDK6: From Discovery to Therapy

    Charles J. Sherr;David Beach;Geoffrey I. Shapiro

  • Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

    James E. Butrynski;David R. D’Adamo;Jason L. Hornick;Paola Dal Cin

  • PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

    Jeffrey A. Engelman;Kreshnik Zejnullahu;Christopher Michael Gale;Eugene Lifshits

  • Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

    Panagiotis A. Konstantinopoulos;Raphael Ceccaldi;Geoffrey I. Shapiro;Alan D. D'Andrea

  • First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Josep Tabernero;Geoffrey I. Shapiro;Patricia M. LoRusso;Andres Cervantes

  • CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

    Jiehui Deng;Jiehui Deng;Eric S. Wang;Russell W. Jenkins;Shuai Li

  • HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

    David M. Hyman;Sarina A. Piha-Paul;Helen Won;Jordi Rodon

  • Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

    Amita Patnaik;Lee S. Rosen;Sara M. Tolaney;Anthony W. Tolcher

  • Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

    Leena Gandhi;D. Ross Camidge;Moacyr Ribeiro De Oliveira;Philip Bonomi

  • Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

    Charles M. Rudin;Christine L. Hann;Edward B. Garon;Moacyr Ribeiro de Oliveira

  • Anticancer drug targets: cell cycle and checkpoint control

    Geoffrey I. Shapiro;J. Wade Harper

Frequent Co-Authors

Patricia LoRusso
Patricia LoRusso Yale University
Sara M. Tolaney
Sara M. Tolaney Harvard University
Kwok-Kin Wong
Kwok-Kin Wong New York University
Alan D. D'Andrea
Alan D. D'Andrea Dana-Farber Cancer Institute
Jeffrey W. Clark
Jeffrey W. Clark Harvard University
Scott J. Rodig
Scott J. Rodig Harvard University
Pasi A. Jänne
Pasi A. Jänne Harvard University
Matthew Meyerson
Matthew Meyerson Harvard University
Ursula A. Matulonis
Ursula A. Matulonis Harvard University
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a wide range of related online degrees and career pathways. Many students who aspire to work in healthcare choose alternative programs that align with their personal interests and career goals.

For those interested in the business and management side of healthcare, pursuing a best online healthcare administration degree can prepare you for leadership roles in hospitals, clinics, or health organizations. If you are a registered nurse seeking career advancement, consider the adn to fnp bridge programs—these flexible pathways help RNs become family nurse practitioners.

Passionate about nutrition and community health? An online nutritionist degree can lead to roles in wellness, education, and public health initiatives. For those aiming for high-level healthcare management, look for online mha programs cahme accredited, which ensure rigorous standards and broader career opportunities.

These online pathways offer flexibility, diverse career options, and the opportunity to impact patient care beyond traditional medical degrees.

Best Scientists Citing Geoffrey I. Shapiro

Trending Scientists

Recently Published Articles